Comparison · NCT00624052-sae
Telmisartan 40mg and Amlodipine 10mg vs Telmisartan 80mg and Amlodipine 10mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Telmisartan 40mg and Amlodipine 10mg vs Telmisartan 80mg and Amlodipine 10mg: serious adverse events. Trial comparisons, record NCT00624052-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00624052-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00477 | 0.00186 | 0.0122 | wilson | |
| Risk in group 2 | 0.0213 | 0.0125 | 0.0361 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0165 | -0.0316 | -0.00498 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.224 | 0.0735 | 0.685 | log | |
| Odds ratio, group 1 over group 2 | 0.221 | 0.0716 | 0.68 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Telmisartan 40mg and Amlodipine 10mg than on Telmisartan 80mg and Amlodipine 10mg | 60.6 | 31.7 | 201 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Telmisartan 40mg and Amlodipine 10mg | The 838 participants in the telmisartan 40mg/amlodipine 10mg group includes all participants | 4 | 838 | EG000 |
| Group 2 | Telmisartan 80mg and Amlodipine 10mg | The 611 participants in the telmisartan 80mg/amlodipine 10mg (T80/A10) group include 436 patients in the randomised T80/A10 group + 91 patients in the uptitrated T80/A10 group + XX patients in the T80/A10 + add-on group | 13 | 611 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From day of first dose through to the day after last dose
Source ClinicalTrials.gov
Trial
- Title
- 26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
- NCT number
- NCT00624052
- Phases
- PHASE3
- Conditions
- Hypertension
- Interventions
- fixed-dose combination of telmisartan 40mg+amlodipine 10mg, fixed-dose combination of telmisartan 80mg+amlodipine10mg
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2010-03-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00624052?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00624052-sae